On April 28th, 2023, Imexpharm Pharmaceutical Joint Stock Company (Imexpharm) held its annual general meeting of shareholders for the 2023-2027 term. In attendance was Mr. Doan Tan Buu, Vice Chairman of the Provincial People's Committee.
Underpinned by a right strategic direction and a strong commitment to execution, Imexpharm delivered outstanding results during the 2018-2022 term. The company achieved an average annual growth of 8.5% in net revenue, a 13.8% increase in pre-tax profit, and a 5.3% rise in average employee income. In 2022 alone, Imexpharm recorded total net revenue of VND 1,668 billion, marking a 29.9% year-on-year increase and surpassing its full-year target by 115.1%. After-tax profit also grew by 12.8% compared to the previous year, reflecting the company’s consistent financial strength and growth momentum.
Imexpharm's Shareholders’ General Meeting
Facing both favorable and challenging forecasts, Imexpharm set its business goals of 2023, targeting VND 1,750 billion in net revenue, a 6.5% year-on-year increase, and a pre-tax profit of VND 350 billion, up 20.1% compared to 2022. By 2023-2027 term, Imexpharm’s goal is to achieve VND3,200 billion in net revenue with an average compound annual growth rate (CAGR) of 16.3%. Pre-tax profit is also expected to reach VND640 billion, also with an average compound annual growth rate of 16.3%. To achieve these goals, Imexpharm has outlined strategic solutions for the 2023-2027 term, focusing on boosting business activities, finance, production, research and development (R&D) and human resource development.
Amidst a landscape of both promising opportunities and potential challenges, Imexpharm has established ambitious business objectives for 2023, targeting a net revenue of VND 1,750 billion, representing a 6.5% increase from the previous year, alongside a pre-tax profit target of VND 350 billion, up 20.1% compared to 2022. Looking forward to the 2023-2027 term, Imexpharm envisions achieving a substantial net revenue of VND 3,200 billion, reflecting a remarkable average compound annual growth rate (CAGR) of 16.3%. Similarly, the pre-tax profit is expected to reach VND 640 billion, also achieving an average CAGR of 16.3%. To realize these strategic ambitions, Imexpharm has formulated a comprehensive set of initiatives for the 2023-2027 period, focusing on enhancing operational efficiency, strengthening financial performance, optimizing production processes, advancing research and development (R&D), and fostering human resource development.
Vice Chairman of the Provincial People's Committee, Mr. Đoàn Tấn Bửu, speaking at the Imexpharm Shareholders’ General Meeting
At the Imexpharm Shareholders' General Meeting, Mr. Đoàn Tấn Bửu, Vice Chairman of the Provincial People's Committee, expressed his admiration for the company's impressive performance. He emphasized that these accomplishments not only reflect Imexpharm's strong operational success but also provide a solid foundation for the company's next phase of growth and development.
In addition, he extended his gratitude for Imexpharm's unwavering commitment and support over the years, particularly in enhancing the province’s welfare, education, and human resource development. With clearly defined goals and strategic plans in place, combined with a dedicated workforce and strong shareholder backing, Imexpharm is confident in its ability to achieve success and reach new milestones in the coming years. The Provincial People's Committee also pledged to support and create favorable conditions for Imexpharm's production and business activities moving forward.
As part of the program, the General Meeting elected the Board of Directors for Imexpharm Joint Stock Company for the 2023-2027 term. Ms. Chun Chaerhan, Head of Vietnam at SK Supex Council, South Korea, was elected as the Chairwoman of the Board.
Author: Y DU - Đồng Tháp Online Newspaper